Limerick NeuroSciences changes name to Limerick BioPharma

The company has also introduced changes to its website, which presents current information about Limerick BioPharma and provides an overview of its proprietary efflux pump activators.

Limerick has identified a proprietary means of improving existing therapeutics by chemically modulating bioavailability and is applying this technology to the development of safer and more potent pharmaceuticals.

Limerick’s lead compound is an NCE transport activator that has shown specific protection against kidney and islet cell toxicities when paired with a well known immunosuppressive. This compound will enter the clinic in early 2009.